Skin Dendritic Cell Targeting via Microneedle Arrays Laden with Antigen-Encapsulated Poly-d,l-lactide-co-Glycolide Nanoparticles Induces Efficient Antitumor and Antiviral Immune Responses

The efficacious delivery of antigens to antigen-presenting cells (APCs), in particular, to dendritic cells (DCs), and their subsequent activation remains a significant challenge in the development of effective vaccines. This study highlights the potential of dissolving microneedle (MN) arrays laden with nanoencapsulated antigen to increase vaccine immunogenicity by targeting antigen specifically to contiguous DC networks within the skin. Following in situ uptake, skin-resident DCs were able to deliver antigen-encapsulated poly-d,l-lactide-co-glycolide (PGLA) nanoparticles to cutaneous draining lymph nodes where they subsequently induced significant expansion of antigen-specific T cells. Moreover, we show that antigen-encapsulated nanoparticle vaccination via microneedles generated robust antigen-specific cellular immune responses in mice. This approach provided complete protection in vivo against both the development of antigen-expressing B16 melanoma tumors and a murine model of para-influenza, through the activation of antigen-specific cytotoxic CD8+ T cells that resulted in efficient clearance of tumors and virus, respectively. In addition, we show promising findings that nanoencapsulation facilitates antigen retention into skin layers and provides antigen stability in microneedles. Therefore, the use of biodegradable polymeric nanoparticles for selective targeting of antigen to skin DC subsets through dissolvable MNs provides a promising technology for improved vaccination efficacy, compliance, and coverage.

[1]  J L Pedraz,et al.  Size dependent immune response after subcutaneous, oral and intranasal administration of BSA loaded nanospheres. , 2002, Vaccine.

[2]  Amit Kumar,et al.  Microneedle-mediated transcutaneous immunization with plasmid DNA coated on cationic PLGA nanoparticles. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[3]  B. Malissen,et al.  CD64 distinguishes macrophages from dendritic cells in the gut and reveals the Th1‐inducing role of mesenteric lymph node macrophages during colitis , 2012, European journal of immunology.

[4]  Jung-Hwan Park,et al.  Microneedles for drug and vaccine delivery. , 2012, Advanced drug delivery reviews.

[5]  B. Gander,et al.  Encapsulation of peptides in biodegradable microspheres prolongs their MHC class-I presentation by dendritic cells and macrophages in vitro. , 2003, Vaccine.

[6]  M. Miller,et al.  The cost of unsafe injections. , 1999, Bulletin of the World Health Organization.

[7]  Mark R. Prausnitz,et al.  Local Response to Microneedle-Based Influenza Immunization in the Skin , 2012, mBio.

[8]  P. Uzor,et al.  Perspectives on Transdermal Drug Delivery , 2011 .

[9]  W. Heath,et al.  Defective TCR expression in transgenic mice constructed using cDNA‐based α‐ and β‐chain genes under the control of heterologous regulatory elements , 1998, Immunology and cell biology.

[10]  A. Krieg,et al.  Biodegradable microspheres containing group B Streptococcus vaccine: immune response in mice. , 2001, American journal of obstetrics and gynecology.

[11]  Scott D. Putney,et al.  Improving protein therapeutics with sustained-release formulations , 1998, Nature Biotechnology.

[12]  Kristin A. Hogquist,et al.  T cell receptor antagonist peptides induce positive selection , 1994, Cell.

[13]  宇都 倫史 Targeting of antigen to dendritic cells with poly(γ-glutamic acid) nanoparticles induces antigen-specific humoral and cellular immunity , 2007 .

[14]  J. Curran,et al.  De novo generation of a non-segmented negative strand RNA virus with a bicistronic gene. , 2009, Virus research.

[15]  P. Perrin,et al.  Dynamics and function of Langerhans cells in vivo: dermal dendritic cells colonize lymph node areas distinct from slower migrating Langerhans cells. , 2005, Immunity.

[16]  Kylie M. Price,et al.  Tumor Immunotherapy by Epicutaneous Immunization Requires Langerhans Cells1 , 2008, The Journal of Immunology.

[17]  A. Kissenpfennig,et al.  Microneedle-mediated vaccine delivery: Harnessing cutaneous immunobiology to improve efficacy , 2012, Expert opinion on drug delivery.

[18]  M. Prausnitz,et al.  Transdermal Influenza Immunization with Vaccine-Coated Microneedle Arrays , 2009, PLoS ONE.

[19]  E. Devilard,et al.  CD207+ CD103+ dermal dendritic cells cross-present keratinocyte-derived antigens irrespective of the presence of Langerhans cells , 2010, The Journal of experimental medicine.

[20]  Sudesh Kumar Yadav,et al.  Biodegradable polymeric nanoparticles based drug delivery systems. , 2010, Colloids and surfaces. B, Biointerfaces.

[21]  John Samuel,et al.  Analysis of Poly(D,L-Lactic-Co-Glycolic Acid) Nanosphere Uptake by Human Dendritic Cells and Macrophages In Vitro , 2002, Pharmaceutical Research.

[22]  R. Gupta,et al.  Biodegradable microspheres as controlled-release tetanus toxoid delivery systems. , 1994, Vaccine.

[23]  V. Labhasetwar,et al.  Biodegradable nanoparticles for cytosolic delivery of therapeutics. , 2007, Advanced drug delivery reviews.

[24]  B. Gilmore,et al.  Gentamicin-loaded nanoparticles show improved antimicrobial effects towards Pseudomonas aeruginosa infection , 2012, International journal of nanomedicine.

[25]  J. Stockman,et al.  Dissolving polymer microneedle patches for influenza vaccination , 2012 .

[26]  Sai T Reddy,et al.  In vivo targeting of dendritic cells in lymph nodes with poly(propylene sulfide) nanoparticles. , 2006, Journal of controlled release : official journal of the Controlled Release Society.

[27]  Y. Nishioka,et al.  Lymphatic targeting with nanoparticulate system. , 2001, Advanced drug delivery reviews.

[28]  R. Steinman Dendritic cells in vivo: a key target for a new vaccine science. , 2008, Immunity.

[29]  B. Gander,et al.  Encapsulation of proteins and peptides into biodegradable poly(D,L-lactide-co-glycolide) microspheres prolongs and enhances antigen presentation by human dendritic cells. , 2006, Vaccine.

[30]  Jean Paul Remon,et al.  Polymeric multilayer capsule-mediated vaccination induces protective immunity against cancer and viral infection. , 2012, ACS nano.

[31]  Sven Burgdorf,et al.  Endocytosis mechanisms and the cell biology of antigen presentation. , 2008, Current opinion in immunology.

[32]  Thakur Raghu Raj Singh,et al.  Optical coherence tomography is a valuable tool in the study of the effects of microneedle geometry on skin penetration characteristics and in-skin dissolution. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[33]  M. Plebanski,et al.  Vaccines that facilitate antigen entry into dendritic cells , 2004, Immunology and cell biology.

[34]  S. Muller,et al.  Immunity under the skin: potential application for topical delivery of vaccines. , 2003, Vaccine.

[35]  D. Brown,et al.  Tumours can act as adjuvants for humoral immunity , 2001, Immunology.

[36]  R. Steinman,et al.  Dendritic cells and the control of immunity , 1998, Nature.

[37]  C. Katlama,et al.  Preferential Amplification of CD8 Effector-T Cells after Transcutaneous Application of an Inactivated Influenza Vaccine: A Randomized Phase I Trial , 2010, PloS one.

[38]  G. Kwon,et al.  Uptake of poly(D,L-lactic-co-glycolic acid) microspheres by antigen-presenting cells in vivo. , 2002, Journal of biomedical materials research.

[39]  G. Glenn,et al.  Dose sparing with intradermal injection of influenza vaccine. , 2004, The New England journal of medicine.

[40]  Ryan F. Donnelly,et al.  Design, Optimization and Characterisation of Polymeric Microneedle Arrays Prepared by a Novel Laser-Based Micromoulding Technique , 2010, Pharmaceutical Research.

[41]  T. Uchida,et al.  Oral delivery of poly(lactide-co-glycolide) microspheres containing ovalbumin as vaccine formulation: particle size study. , 1994, Biological & pharmaceutical bulletin.

[42]  Y. Tokura,et al.  Percutaneous peptide immunization via corneum barrier-disrupted murine skin for experimental tumor immunoprophylaxis. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[43]  F. Newman,et al.  Serum antibody responses after intradermal vaccination against influenza. , 2004, The New England journal of medicine.

[44]  S. Kaveri,et al.  Recent advances in the administration of vaccines for infectious diseases: microneedles as painless delivery devices for mass vaccination. , 2011, Drug discovery today.

[45]  Li Wu,et al.  CD4 and CD8 Expression by Dendritic Cell Subtypes in Mouse Thymus and Spleen1 , 2000, The Journal of Immunology.

[46]  Mark R Prausnitz,et al.  Microneedles for transdermal drug delivery. , 2004, Advanced drug delivery reviews.

[47]  Praveen Elamanchili,et al.  Characterization of poly(D,L-lactic-co-glycolic acid) based nanoparticulate system for enhanced delivery of antigens to dendritic cells. , 2004, Vaccine.

[48]  S. Vyas,et al.  Strong systemic and mucosal immune responses to surface-modified PLGA microspheres containing recombinant hepatitis B antigen administered intranasally. , 2006, Vaccine.

[49]  R. Steinman Dendritic cells: versatile controllers of the immune system , 2007, Nature Medicine.

[50]  Vladimir P Torchilin,et al.  Multifunctional nanocarriers. , 2006, Advanced drug delivery reviews.

[51]  T. Kündig,et al.  Immunity in response to particulate antigen-delivery systems. , 2005, Advanced drug delivery reviews.

[52]  Jian Qin,et al.  The importance of an endotoxin-free environment during the production of nanoparticles used in medical applications. , 2006, Nano letters.

[53]  Anil Mahapatro,et al.  Biodegradable nanoparticles are excellent vehicle for site directed in-vivo delivery of drugs and vaccines , 2011, Journal of nanobiotechnology.

[54]  Jayanth Panyam,et al.  Biodegradable nanoparticles for drug and gene delivery to cells and tissue. , 2003, Advanced drug delivery reviews.

[55]  Elazer R. Edelman,et al.  Adv. Drug Delivery Rev. , 1997 .